Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival : A Systematic Review and Meta-analysis

enthalten in: JAMA oncology | 2016

von Douxfils, J. | Haguet, H. | Mullier, F. | +3

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis

enthalten in: Expert opinion on drug safety | 2016

von Haguet, H. | Douxfils, J. | Mullier, F. | +3